Skip to content

Investigation of diagnosis and treatment status of patients with autoimmune gastritis

Investigation of diagnosis and treatment status of patients with autoimmune gastritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099035
Enrollment
Unknown
Registered
2025-03-18
Start date
2025-05-05
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Gastritis

Interventions

Autoimmune Gastritis:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Male or female, aged between 18-70 years old; Symptoms such as bloating and poor appetite; Within 3 months prior to enrollment, there were positive gastroscopy and pathological results and/or serum antibody markers, which met the diagnostic criteria for AIG proposed by the Japanese Society of Gastrointestinal Endoscopy: 1 Endoscopic examination and/or histopathological examination show severe atrophy of the mucosa from the gastric body to the gastric fundus; 2. Positive gastric autoantibodies - positive for anti parietal cell (APCA) and/or anti intrinsic factor (IFA) antibodies. The participants meet both 1 and 2 criteria simultaneously; The patient voluntarily signs an informed consent form.

Exclusion criteria

Exclusion criteria: Untreated patients with active Helicobacter pylori infection Pathological examination accompanied by intraepithelial neoplasia; Accompanied by other gastric mucosal lesions [such as active ulcers, active bleeding, gastric cancer, etc.]; After subtotal gastrectomy; Within the past three months, endoscopic treatment such as ESD (endoscopic mucosal dissection) and EMR (endoscopic mucosal resection) has been performed for intraepithelial neoplasia and adenoma; Individuals with obvious mental behavioral abnormalities and emotional disorders; Serious cardiovascular and cerebrovascular diseases, abnormal liver and kidney function; Other malignant tumors are currently under treatment (chemotherapy, radiotherapy, immunotherapy, etc.); Pregnant or lactating women; The patient did not sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Characteristics of AIG incidence population: age, gender;Past history: anemia, type I diabetes, thyroid disease, other autoimmune diseases;Previously/Currently Infected with Hp;Clinical symptoms of AIG (such as abdominal distension, abdominal pain/epigastric pain, early satiety, postprandial satiety, anorexia, nausea, fatigue, anemia, numbness of limbs, skin rash, etc.), the significance of the above symptoms to diagnosis and their impact on incidence rate;Positive detection rate;

Countries

China

Contacts

Public ContactLi Jingnan

Peking Union Medical College Hospital

lijn2008@126.com+86 136 0123 5229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026